---
title: The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome
nct_id: NCT02093858
overall_status: UNKNOWN
sponsor: Central South University
study_type: OBSERVATIONAL
primary_condition: Schizophrenia
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02093858.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02093858"
ct_last_update_post_date: 2014-03-21
last_seen_at: "2026-05-12T07:31:52.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome

**NCT ID:** [NCT02093858](https://clinicaltrials.gov/study/NCT02093858)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 212
- **Lead Sponsor:** Central South University
- **Conditions:** Schizophrenia, Metabolic Syndrome
- **Start Date:** 2014-04
- **Completion Date:** 2017-12
- **CT.gov Last Update:** 2014-03-21

## Brief Summary

Almost all of antipsychotics can induce metabolic syndrome,Genetic factors play a key role in the development of metabolic syndrome,TCF7L2 and SLC30A8 are strongestly correlated with metabolic syndrome.Moreover,Antipsychotics have an effect on the expression of TCF7L2 and SLC30A8 genes.It indicates the variations of TCF7L2 and SLC30A8 play an important part in the development of antipsychotics-induced metabolic syndrome.

## Detailed Description

* In this study, we will determine the effect of olanzapine on the expression of TCF7L2 and SLC30A8.
* The relationship of the polymorphism of TCF7L2 and SLC30A8 with antipsychotic-induced metabolic syndrome in schizophrenia patients.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 45 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Clinical diagnosis of first episode schizophrenia
* Must be able to swallow tablets
* Take only one antipsychotics

Exclusion Criteria:

* liver or renal or cardiovascular diseases
* pregnant or lactating women
* drug and alcohol dependence
```

## Arms

- **olanzapine** — 15-25mg/day for 24 weeks

## Primary Outcomes

- **Change in weight and blood glucose** _(time frame: 24 weeks)_

## Secondary Outcomes

- **Change of the blood pressure and blood lipid** _(time frame: 24 weeks)_

## Locations (1)

- Mental Health Institute, Changsha, Hunan, China

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.mental health institute|changsha|hunan|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02093858.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02093858*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*